Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue	$ 7,520,767	$ 5,958,544	$ 11,275,156	$ 9,405,252
Cost of revenue	2,195,255	1,677,488	3,650,601	2,816,594
Gross profit	5,325,512	4,281,056	7,624,555	6,588,658
Operating expenses:
Research and development	1,007,224	564,235	1,963,438	1,041,225
Selling, clinical and marketing	2,777,135	2,271,937	5,138,980	4,302,488
General and administrative	2,656,217	2,547,890	5,525,968	5,018,947
Total operating expenses	6,440,576	5,384,062	12,628,386	10,362,660
Loss from operations	(1,115,064)	(1,103,006)	(5,003,831)	(3,774,002)
Other (income) expense, net
Interest income	(107,242)	(103,439)	(242,535)	(189,753)
Other expense, net	0	5,631	0	5,631
Loss on equity investment	0	12,514	0	29,716
Total other expense (income), net	(107,242)	(85,294)	(242,535)	(154,406)
Loss before income taxes	(1,007,822)	(1,017,712)	(4,761,296)	(3,619,596)
Income tax expense (benefit)	113,785	(3,562)	195,943	38,849
Net loss	$ (1,121,607)	$ (1,014,150)	$ (4,957,239)	$ (3,658,445)
Weighted average number of common shares outstanding:
Basic	37,368,488	27,992,928	37,060,543	26,000,216
Diluted	37,368,488	27,992,928	37,060,543	26,000,216
Net loss per share attributable to common stockholders
Basic	$ (0.03)	$ (0.04)	$ (0.13)	$ (0.14)
Diluted	$ (0.03)	$ (0.04)	$ (0.13)	$ (0.14)
Product revenue
Revenue	$ 7,520,767	$ 4,243,624	$ 11,275,156	$ 7,690,332
License revenue
Revenue	$ 0	$ 1,714,920	$ 0	$ 1,714,920